Brief: Innate Pharma: First Patient Dosed In Study Of IPH6501 In Non-Hodgkin's Lymphoma

Innate Pharma SA

06/03/2024 06:05

March 6 (Reuters) - Innate Pharma SA  IPH.PA :
    * FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF IPH6501 IN
RELAPSED
/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
    * STUDY IS PLANNED TO ENROLL UP TO 184 PATIENTS

Source text for Eikon:  ID:nBw5HvWLqa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))